Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children (LAIV)

22 września 2011 zaktualizowane przez: MedImmune LLC

A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children

The primary objective of this study is to demonstrate the immunologic noninferiority of Q/LAIV to FluMist in children 2 to 17 years of age.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

The randomized, double-blind study was designed to demonstrate the immunologic noninferiority of Q/LAIV compared to FluMist in children 2-17 years by comparing the strain-specific post-dose geometric mean titers of hemagglutination inhibition antibodies. Children were randomized 3:1:1 to receive Q/LAIV or one of two FluMist vaccines. Subjects 9-17 years of age received a single dose, and those 2-8 years of age received two doses one month apart. Serum was obtained 1 month after dose 1 except in influenza vaccine-naive subjects 2-8 years old, when it was obtained after dose 2. Safety and tolerability were also assessed.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

2312

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35209
        • Research Site
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • Research Site
    • Arizona
      • Tucson, Arizona, Stany Zjednoczone, 85712
        • Research Site
    • Arkansas
      • Benton, Arkansas, Stany Zjednoczone, 72019
        • Research Site
      • Bentonville, Arkansas, Stany Zjednoczone, 72712
        • Research Site
      • Fayetteville, Arkansas, Stany Zjednoczone, 72703
        • Research Site
      • Jonesboro, Arkansas, Stany Zjednoczone, 72401
        • Research Site
      • Little Rock, Arkansas, Stany Zjednoczone, 72205
        • Research Site
    • California
      • Anaheim, California, Stany Zjednoczone, 92805
        • Research Site
      • Fountain Valley, California, Stany Zjednoczone, 92708
        • Research Site
      • Fresno, California, Stany Zjednoczone, 93720
        • Research Site
      • Long Beach, California, Stany Zjednoczone, 90808
        • Research Site
      • Paramount, California, Stany Zjednoczone, 90723
        • Research Site
      • Sacramento, California, Stany Zjednoczone, 95816
        • Research Site
      • San Francisco, California, Stany Zjednoczone, 94102
        • Research Site
      • West Covina, California, Stany Zjednoczone, 91790
        • Research Site
    • Delaware
      • Wilmington, Delaware, Stany Zjednoczone, 19899
        • Research Site
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33432
        • Research Site
      • Jacksonville, Florida, Stany Zjednoczone, 32223
        • Research Site
      • Miami, Florida, Stany Zjednoczone, 33126
        • Research Site
      • Miami, Florida, Stany Zjednoczone, 33173
        • Research Site
      • Ponte Vedra, Florida, Stany Zjednoczone, 32081
        • Research Site
      • South Miami, Florida, Stany Zjednoczone, 33143
        • Research Site
      • St. Petersburg, Florida, Stany Zjednoczone, 33710
        • Research Site
      • West Palm Beach, Florida, Stany Zjednoczone, 33409
        • Research Site
    • Georgia
      • Dalton, Georgia, Stany Zjednoczone, 30721
        • Research Site
      • Marietta, Georgia, Stany Zjednoczone, 30062
        • Research Site
      • Woodstock, Georgia, Stany Zjednoczone, 30189
        • Research Site
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60614
        • Research Site
      • Dekalb, Illinois, Stany Zjednoczone, 60115
        • Research Site
    • Kansas
      • Newton, Kansas, Stany Zjednoczone, 67005
        • Research Site
      • Overland Park, Kansas, Stany Zjednoczone, 66210
        • Research Site
      • Wichita, Kansas, Stany Zjednoczone, 67207
        • Research Site
    • Kentucky
      • Bardstown, Kentucky, Stany Zjednoczone, 40004
        • Research Site
      • Lexington, Kentucky, Stany Zjednoczone, 40509
        • Research Site
    • Louisiana
      • Metairie, Louisiana, Stany Zjednoczone, 70006
        • Research Site
    • Michigan
      • Kalamazoo, Michigan, Stany Zjednoczone, 49008
        • Research Site
      • Niles, Michigan, Stany Zjednoczone, 49120
        • Research Site
      • Stevensville, Michigan, Stany Zjednoczone, 49127
        • Research Site
    • Minnesota
      • Plymouth, Minnesota, Stany Zjednoczone, 55441
        • Research Site
      • St. Paul, Minnesota, Stany Zjednoczone, 55108
        • Research Site
    • Missouri
      • Kansas City, Missouri, Stany Zjednoczone, 64114
        • Research Site
      • St. Louis, Missouri, Stany Zjednoczone, 63141
        • Research Site
      • St. Louis, Missouri, Stany Zjednoczone, 63104
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68134
        • Research Site
      • Omaha, Nebraska, Stany Zjednoczone, 68198-2162
        • Research Site
      • Papillion, Nebraska, Stany Zjednoczone, 68046
        • Research Site
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89104
        • Research Site
    • New Hampshire
      • Lebanon, New Hampshire, Stany Zjednoczone, 03756
        • Research Site
    • New Mexico
      • Albuquerque, New Mexico, Stany Zjednoczone, 87108
        • Research Site
    • New York
      • Binghamton, New York, Stany Zjednoczone, 13901
        • Research Site
      • Brooklyn, New York, Stany Zjednoczone, 11201
        • Research Site
      • Mineola, New York, Stany Zjednoczone, 11501
        • Research Site
      • Rochester, New York, Stany Zjednoczone, 14618
        • Research Site
      • Rochester, New York, Stany Zjednoczone, 14609
        • Research Site
    • North Carolina
      • Asheboro, North Carolina, Stany Zjednoczone, 27203
        • Research Site
      • Boone, North Carolina, Stany Zjednoczone, 28607
        • Research Site
      • Clyde, North Carolina, Stany Zjednoczone, 28721
        • Research Site
      • Mount Pleasant, North Carolina, Stany Zjednoczone, 29464
        • Research Site
      • Raleigh, North Carolina, Stany Zjednoczone, 27609
        • Research Site
      • Raleigh, North Carolina, Stany Zjednoczone, 27607
        • Research Site
      • Winston-Salem, North Carolina, Stany Zjednoczone, 27103
        • Research Site
    • North Dakota
      • Bismark, North Dakota, Stany Zjednoczone, 58501
        • Research Site
      • Fargo, North Dakota, Stany Zjednoczone, 88104
        • Research Site
    • Ohio
      • Akron, Ohio, Stany Zjednoczone, 44308
        • Research Site
      • Cincinnati, Ohio, Stany Zjednoczone, 45231
        • Research Site
      • Cincinnati, Ohio, Stany Zjednoczone, 45245
        • Research Site
      • Cincinnati, Ohio, Stany Zjednoczone, 45249
        • Research Site
      • Dayton, Ohio, Stany Zjednoczone, 45415
        • Research Site
      • Huber Heights, Ohio, Stany Zjednoczone, 45424
        • Research Site
    • Oklahoma
      • Norman, Oklahoma, Stany Zjednoczone, 73071
        • Research Site
      • Yukon, Oklahoma, Stany Zjednoczone, 73099
        • Research Site
    • Pennsylvania
      • Altoona, Pennsylvania, Stany Zjednoczone, 16602
        • Research Site
      • Erie, Pennsylvania, Stany Zjednoczone, 16505
        • Research Site
      • Greenville, Pennsylvania, Stany Zjednoczone, 16125
        • Research Site
      • Harleysville, Pennsylvania, Stany Zjednoczone, 19438
        • Research Site
      • Hermitage, Pennsylvania, Stany Zjednoczone, 16148
        • Research Site
      • Latrobe, Pennsylvania, Stany Zjednoczone, 15650
        • Research Site
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15241
        • Research Site
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15220
        • Research Site
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15227
        • Research Site
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15237
        • Research Site
      • Scotland, Pennsylvania, Stany Zjednoczone, 17254
        • Research Site
      • Sellersville, Pennsylvania, Stany Zjednoczone, 18960
        • Research Site
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29425
        • Research Site
      • Charleston, South Carolina, Stany Zjednoczone, 29406
        • Research Site
      • Mt. Pleasant, South Carolina, Stany Zjednoczone, 29464
        • Research Site
    • Tennessee
      • Bristol, Tennessee, Stany Zjednoczone, 37620
        • Research Site
      • Clarksville, Tennessee, Stany Zjednoczone, 37043
        • Research Site
      • Kingsport, Tennessee, Stany Zjednoczone, 37660
        • Research Site
      • Nashville, Tennessee, Stany Zjednoczone, 37232
        • Research Site
    • Texas
      • Arlington, Texas, Stany Zjednoczone, 76018
        • Research Site
      • Ft. Worth, Texas, Stany Zjednoczone, 76107
        • Research Site
      • Ft. Worth, Texas, Stany Zjednoczone, 76135
        • Research Site
      • Longview, Texas, Stany Zjednoczone, 75605
        • Research Site
      • New Branfels, Texas, Stany Zjednoczone, 78130
        • Research Site
      • Sugarland, Texas, Stany Zjednoczone, 77479
        • Research Site
    • Utah
      • Draper, Utah, Stany Zjednoczone, 84020
        • Research Site
      • Layton, Utah, Stany Zjednoczone, 84041
        • Research Site
      • Orem, Utah, Stany Zjednoczone, 84057
        • Research Site
      • Roy, Utah, Stany Zjednoczone, 84067
        • Research Site
      • Salt Lake City, Utah, Stany Zjednoczone, 84124
        • Research Site
      • South Jordan, Utah, Stany Zjednoczone, 84095
        • Research Site
      • Syracuse, Utah, Stany Zjednoczone, 84075
        • Research Site
    • Virginia
      • Burke, Virginia, Stany Zjednoczone, 22015
        • Research Site
      • Charlottesville, Virginia, Stany Zjednoczone, 22902
        • Research Site
      • Vienna, Virginia, Stany Zjednoczone, 33180
        • Research Site
      • Virginia Beach, Virginia, Stany Zjednoczone, 23454
        • Research Site
    • West Virginia
      • Huntington, West Virginia, Stany Zjednoczone, 25701
        • Research Site
    • Wisconsin
      • Franklin, Wisconsin, Stany Zjednoczone, 53123
        • Research Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

2 lata do 17 lat (Dziecko)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Male or female
  • Age 2 through 17 years at the time of randomization
  • Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive in the EU, and written informed assent if applicable) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Females of childbearing potential, unless surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), has sterile male partner, is premenarchal, or practices abstinence, must have used an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap with spermicide, or use of a condom with spermicide by the sexual partner) for 30 days prior to the first dose of investigational product, and must agree to continue using such precautions for 60 days after the final dose of investigational product
  • A subject who is considered by the investigator to be at risk of pregnancy must also have a negative urine pregnancy test at screening and, if screening and Day 0 do not occur on the same day, on the day of vaccination prior to randomization. Investigator judgment is required to assess each subject's need for pregnancy testing
  • Healthy by medical history and physical examination OR presence of stable underlying chronic medical condition for which hospitalization has not been required in the previous year
  • Able to complete follow-up period of 180 days post last dose of vaccine as required by the protocol
  • Subject/legal representative is available by telephone
  • Child's legal representative is able to understand and comply with the requirements of the protocol, as judged by the investigator

Exclusion Criteria:

  • Acute illness or evidence of significant active infection at randomization;
  • Fever ≥ 100.4°F (38.0°C) at randomization
  • History of asthma, or in children < 5 years of age, history of recurrent wheezing
  • Any drug therapy from 15 days prior to randomization or expected drug therapy through 28 days post last dose with the exception of the following classes/types of medications, which are allowed:
  • Contraceptives (change in contraceptive type or method is acceptable as long as guidelines are followed for prevention of pregnancy during change);
  • Topical corticosteroids, calcineurin inhibitors, or antifungals for uncomplicated dermatitis;
  • Chronic medications (including those taken on an as-needed basis) that have been well tolerated and were not initiated and/or did not have a dosage change within 90 days prior to randomization.
  • Current or expected receipt of immunosuppressive medications within a 28 day window around any dose, including an immunosuppressive dose of corticosteroids, which is defined as ≥ 20 mg/day of prednisone or its equivalent, given daily or on alternate days for ≥ 15 days) (intranasal, intra-articular, and topical corticosteroids are permitted); Note: topical corticosteroids for uncomplicated dermatitis may be used throughout the study according to the judgment of the investigator; topical calcineurin inhibitors may be used in accordance with their package insert at entry and during study participation
  • Receipt of immunoglobulin or blood products within 90 days before randomization into the study or expected receipt during study participation
  • Receipt of any investigational drug therapy within 28 days prior to Dose 1 or planned receipt of any investigational drug therapy through 90 days after final dosing of investigational product (use of licensed agents for indications not listed in the package insert is permitted)
  • Receipt of any nonstudy vaccine within 28 days prior to randomization or planned receipt of nonstudy vaccine through 28 days after final dosing
  • Receipt of any nonstudy seasonal influenza vaccine within 90 days of Dose 1 or planned receipt of nonstudy seasonal influenza vaccine prior to 35 days post last dose of investigational product
  • Any known immunosuppressive condition or immune deficiency disease including known or suspected infection with human immunodeficiency virus (HIV)
  • History of allergic disease or reactions likely to be exacerbated by any component of the investigational product including allergy to eggs, egg proteins, gentamicin, or gelatin or serious, life threatening, or severe reactions to previous influenza vaccinations
  • Use of aspirin or salicylate-containing products within 28 days prior to randomization or expected receipt through 28 days after final vaccination;
  • History of Guillain-Barré syndrome
  • Use of antiviral agents with activity against influenza virus (including amantadine, rimantadine, oseltamivir, and zanamivir) within 28 days prior to first dose of investigational product or anticipated use of such agents within 28 days after last scheduled vaccination
  • Known or suspected mitochondrial encephalomyopathy
  • Pregnant or lactating female
  • History of alcohol or drug abuse that, in the opinion of the investigator, would affect the subject's safety or compliance with study
  • Any condition that, in the opinion of the investigator, might compromise the safety of the subject in the study or would interfere with evaluation of the safety or immunogenicity of the investigational products
  • Subject, legal representative, or immediate family member of subject who is an employee of the clinical study site or who is otherwise involved with the conduct of the study
  • A history of epilepsy, seizure, or an evolving neurological condition except that of a single febrile seizure that occurred 3 or more years prior to enrollment would not disqualify a subject

Note: an individual who initially is excluded from study participation based on one or more of the above time-limited criteria may be reconsidered for enrollment once the condition has resolved as long as the subject continues to meet all other entry criteria and the same SID number is used

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Q/LAIV (MEDI3250)
Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
Biologiczny: Q/LAIV (MEDI3250)
10 ^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
Eksperymentalny: FluMist/B/Yamagata
FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])
Biologiczny: FluMist/B/Yamagata
10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
Eksperymentalny: FluMist/B/Victoria
FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004]).
Biologiczny: FluMist/B/Victoria
10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the Comparator FluMist Group.
Ramy czasowe: Day 28 post immunogenicity dose
Noninferior immune response was defined as having the upper bound of the 2-sided 95% confidence intervals (CIs) for the HAI antibody GMT ratio (FluMist comparator divided by Q/LAIV) ≤ 1.5 for each of the 4 strains. .
Day 28 post immunogenicity dose

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
The Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the A/H1N1 Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seroresponse was defined as a ≥ 4-fold rise in HAI antibody titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the A/H3N2 Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seroresponse was defined as a ≥ 4-fold rise in HAI antibody titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the B/Yamagata Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seroresponse was defined as a ≥ 4-fold rise in HAI antibody titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the B/Victoria Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seroresponse was defined as a ≥ 4-fold rise from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Within Each Treatment Arm Who Experienced a Seroresponse to the A/H1N1 Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Within Each Treatment Arm Who Experience Seroresponse to the A/H3N2 Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Within Each Treatment Arm Who Experience Seroresponse to the B/Yamagata Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Within Each Treatment Arm Who Experience Seroresponse to the B/Victoria Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the A/H1N1 Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the A/H3N2 Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the B/Yamagata Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the B/Victoria Strain Post Immunogenicity Dose
Ramy czasowe: Day 0 and Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4. Seroresponse was defined as a ≥ 4-fold rise in HAI titer from baseline.
Day 0 and Day 28 post immunogenicity dose
Percent of Participants (Regardless of Serostatus) Who Achieved an A/H1N1 or A/H3N2 Strain-specific HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Day 28 post immunogenicity dose
Percent of Participants (Regardless of Serostatus) Who Achieved a B/Yamagata HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Day 28 post immunogenicity dose
Percent of Participants (Regardless of Serostatus) Who Achieved a B/Victoria HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Who Achieved an A/H1N1 HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8.
Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Who Achieved an A/H3N2 HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8.
Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Who Achieved a B/Yamagata HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8.
Day 28 post immunogenicity dose
Percent of Serosusceptible Participants Who Achieved a B/Victoria HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Serosusceptible was defined as a baseline HAI titer ≤ 8.
Day 28 post immunogenicity dose
Percent of Seronegative Participants Who Achieved an A/H1N1 HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4.
Day 28 post immunogenicity dose
Percent of Seronegative Participants Who Achieved an A/H3N2 HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4.
Day 28 post immunogenicity dose
Percent of Seronegative Participants Who Achieved a B/Yamagata HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4.
Day 28 post immunogenicity dose
Percent of Seronegative Participants Who Achieved a B/Victoria HAI Antibody Titer ≥ 32 Post Immunogenicity Dose
Ramy czasowe: Day 28 post immunogenicity dose
Seronegative was defined as a baseline HAI titer ≤ 4.
Day 28 post immunogenicity dose
Percent of All Participants Experiencing Each Solicited Symptom From Administration of Investigational Product Through 14 Days Post Dose 1
Ramy czasowe: Days 0-14 Post Dose 1
Solicited symptoms were fever ≥ 100.4°F (38.0°C), runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, decreased activity level (lethargy) OR tiredness/weakness, decreased appetite. Collection of specific solicited symptoms (sore throat, headache, generalized muscle aches) was omitted when, according to the judgment of the investigator, the subject was too young to reliably report a particular symptom.
Days 0-14 Post Dose 1
Percent of Two-dose Participants Experiencing Each Solicited Symptom From Administration of Investigational Product Through 14 Days Post Dose 1
Ramy czasowe: Days 0-14 Post Dose 1
Solicited symptoms were fever ≥ 100.4°F (38.0°C), runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, decreased activity level (lethargy) OR tiredness/weakness, decreased appetite. Collection of specific solicited symptoms (sore throat, headache, generalized muscle aches) was omitted when, according to the judgment of the investigator, the subject was too young to reliably report a particular symptom.
Days 0-14 Post Dose 1
Percent of Two-dose Participants Experiencing Each Solicited Symptom From Administration of Dose 2 During Days 0-14 Post Dose 2
Ramy czasowe: Days 0-14 Post Dose 2
Solicited symptoms were fever ≥ 100.4°F (38.0°C), runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, decreased activity level (lethargy) OR tiredness/weakness, decreased appetite. Collection of specific solicited symptoms (sore throat, headache, generalized muscle aches) was omitted when, according to the judgment of the investigator, the subject was too young to reliably report a particular symptom.
Days 0-14 Post Dose 2
Percent of All Participants Experiencing Any Adverse Event From Administration of Investigational Product Through Day 28 Post Dose 1
Ramy czasowe: Days 0-28 Post Dose 1
Any untoward medical occurrence in a patient or clinical investigation in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Days 0-28 Post Dose 1
Percent of Two-dose Participants Experiencing Any Adverse Event From Administration of Investigational Product Through Day 28 Post Dose 1
Ramy czasowe: Days 0-28 Post Dose 1
Any untoward medical occurrence in a patient or clinical investigation in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Days 0-28 Post Dose 1
Percent of Two-dose Participants Experiencing Any Adverse Event From Administration of Dose 2 Through 28 Days Post Dose 2
Ramy czasowe: Days 0-28 Post Dose 2
Any untoward medical occurrence in a patient or clinical investigation in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Days 0-28 Post Dose 2
Percent of All Participants Reporting Any Serious Adverse Event (SAE) From Administration of Investigational Product Through Day 28 Post Dose 1
Ramy czasowe: Days 0-28 Post Dose 1
SAEs were those AEs that resulted in death; were immediately life threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and that, based on appropriate medical judgement, may have jeopardized the participant and may have required medical or surgical intervention to prevent on the outcomes listed above.
Days 0-28 Post Dose 1
Percent of Two-dose Participants Reporting Any SAE From Administration of Dose 2 During Days 0-28 Post Dose 2
Ramy czasowe: Days 0-28 Post Dose 2
SAEs were those AEs that resulted in death; were immediately life threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and that, based on appropriate medical judgement, may have jeopardized the participant and may have required medical or surgical intervention to prevent on the outcomes listed above.
Days 0-28 Post Dose 2
Percent of All Participants Reporting Any SAE From Administration of Investigational Product Through 180 Days Post Last Dose
Ramy czasowe: Days 0-180 Post Last Dose
SAEs were those AEs that resulted in death; were immediately life threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and that, based on appropriate medical judgement, may have jeopardized the participant and may have required medical or surgical intervention to prevent on the outcomes listed above.
Days 0-180 Post Last Dose
Percent of All Participants Reporting Any New Onset Chronic Disease (NOCD) From Administration of Investigational Product Through 180 Days Post Last Dose
Ramy czasowe: Days 0-180 Post Last Dose
An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant.
Days 0-180 Post Last Dose

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

MedImmune LLC

Śledczy

  • Dyrektor Studium: Judith Falloon, M.D., MedImmune LLC

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 marca 2010

Zakończenie podstawowe (Rzeczywisty)

1 lipca 2010

Ukończenie studiów (Rzeczywisty)

1 grudnia 2010

Daty rejestracji na studia

Pierwszy przesłany

19 marca 2010

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 marca 2010

Pierwszy wysłany (Oszacować)

23 marca 2010

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

26 września 2011

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

22 września 2011

Ostatnia weryfikacja

1 września 2011

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • MI-CP208

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Q/LAIV (MEDI3250)

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Vietnam

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj